Cargando…
Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but more prevalent mutations. This uncertainty reflects the need to develop personalized prescreening platforms for these patients to a...
Autores principales: | Sequiera, Glen Lester, Srivastava, Abhay, Sareen, Niketa, Yan, Weiang, Alagarsamy, Keshav Narayan, Verma, Elika, Aghanoori, Mohamad Reza, Aliani, Michel, Kumar, Ashok, Fernyhough, Paul, Rockman-Greenberg, Cheryl, Dhingra, Sanjiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993122/ https://www.ncbi.nlm.nih.gov/pubmed/35394834 http://dx.doi.org/10.1126/sciadv.abl4370 |
Ejemplares similares
-
Generation and Evaluation of Isogenic iPSC as a Source of Cell Replacement Therapies in Patients with Kearns Sayre Syndrome
por: Lester Sequiera, Glen, et al.
Publicado: (2021) -
Fabrication of Smart Tantalum Carbide MXene Quantum Dots with Intrinsic Immunomodulatory Properties for Treatment of Allograft Vasculopathy
por: Rafieerad, Alireza, et al.
Publicado: (2021) -
Hypoxia-induced 26S proteasome dysfunction increases immunogenicity of mesenchymal stem cells
por: Abu-El-Rub, Ejlal, et al.
Publicado: (2019) -
Hypoxia-induced shift in the phenotype of proteasome from 26S toward immunoproteasome triggers loss of immunoprivilege of mesenchymal stem cells
por: Abu-El-Rub, Ejlal, et al.
Publicado: (2020) -
An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning β-cell survival and cardiovascular conditions in diabetic patients
por: Srivastava, Abhay, et al.
Publicado: (2022)